Treatment of aggressive B‐cell lymphomas
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2407
Abstract: The treatment of aggressive B‐cell lymphomas is in evolution, largely based on the recognition of major genetic and biologic subtypes harboring distinct pathogenetic lesions. In this review, we will consider current treatment options with the… read more here.
Keywords: aggressive cell; chop; treatment; cell lymphomas ... See more keywords
ROBUST: PHASE III RANDOMIZED STUDY OF LENALIDOMIDE/R‐CHOP VS PLACEBO/R‐CHOP IN UNTREATED ABC‐TYPE DIFFUSE LARGE B‐CELL LYMPHOMA AND FEASIBILITY OF CELL OF ORIGIN SUBTYPING
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2440
Abstract: OT01 ROBUST: PHASE III RANDOMIZED STUDY OF LENALIDOMIDE/R‐CHOP VS PLACEBO/ R‐CHOP IN UNTREATED ABC‐TYPE DIFFUSE LARGE B‐CELL LYMPHOMA AND FEASIBILITY OF CELL OF ORIGIN SUBTYPING A. Chiappella* | T.E. Witzig | U. Vitolo | R.… read more here.
Keywords: cell; hematology; oncology; phase iii ... See more keywords
Frontline treatment of diffuse large B‐cell lymphoma: Beyond R‐CHOP
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.2613
Abstract: Although the majority of patients with diffuse large B‐cell lymphoma (DLBCL) can be cured with the standard immunochemotherapy R‐CHOP, one‐third of them relapses with a dismal outcome in most cases. In the recent years, remarkable… read more here.
Keywords: cell; chop; frontline treatment; large cell ... See more keywords
Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera®) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trial
Sign Up to like & getrecommendations! Published in 2022 at "Hematological Oncology"
DOI: 10.1002/hon.3054
Abstract: This study compared the efficacy, safety and immunogenicity of ripertamab (SCT400) and rituximab (Mabthera®) combined with CHOP as the first‐line treatment for Chinese patients with CD20‐positive diffuse large B cell lymphoma (DLBCL). This is a… read more here.
Keywords: cd20 positive; safety; chop; rituximab mabthera ... See more keywords
R‐CHOP VS. R‐CHOP+X FOR NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA: A SYSTEMATIC REVIEW AND META‐ANALYSIS
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.95_2631
Abstract: cancer specific survival and overall survival respectively were 86%, 71% and 57%. Conclusion: A trend for an improvement in all outcomes was found for patients treated with a DS of 1-3, compared to a DS… read more here.
Keywords: newly diagnosed; chop newly; diffuse large; chop chop ... See more keywords
CSC-3436 sensitizes triple negative breast cancer cells to TRAIL-induced apoptosis through ROS-mediated p38/CHOP/death receptor 5 signaling pathways.
Sign Up to like & getrecommendations! Published in 2021 at "Environmental toxicology"
DOI: 10.1002/tox.23372
Abstract: Tumor necrosis factor-related apoptosis-induced ligand (TRAIL) shows little or no toxicity in most normal cells and preferentially induces apoptosis in a variety of malignant cells. However, patients develop resistance to TRAIL, therefore, sensitizing agents that… read more here.
Keywords: chop; csc 3436; cells trail; apoptosis ... See more keywords
Peroxisome proliferator-activated receptor alpha mediates C/EBP homologous protein to protect mice from acute liver failure
Sign Up to like & getrecommendations! Published in 2017 at "Inflammation Research"
DOI: 10.1007/s00011-017-1061-3
Abstract: ObjectivePeroxisome proliferator-activated receptor α (PPARα) activation has been reported to ameliorate liver injury in cases of acute liver failure (ALF). However, its intrinsic protective molecular mechanisms remain largely undetermined. C/EBP homologous protein (CHOP) is an… read more here.
Keywords: chop; expression; inflammation; ppar activation ... See more keywords
Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies
Sign Up to like & getrecommendations! Published in 2021 at "Annals of Hematology"
DOI: 10.1007/s00277-021-04421-2
Abstract: End-of-treatment (EoT) PET/CT is used as a guide to omit radiotherapy (RT) patients with primary mediastinal large B-cell lymphoma (PMBCL). We present the mature and extended results of a retrospective study evaluating the prognostic significance… read more here.
Keywords: d5pss d5pss; pet; d5pss; primary mediastinal ... See more keywords
Efficacy and safety comparison between R-CHOP and modified NHL-BFM-90 regimens in children and adolescents with diffuse large B-cell lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Hematology"
DOI: 10.1007/s00277-022-04754-6
Abstract: Studies comparing the efficacy and safety of R-CHOP and modified non-Hodgkin lymphoma Berlin-Frankfurt-Münster-90 (NHL-BFM-90) regimens in children and adolescents with diffuse large B-cell lymphoma (DLBCL) are lacking. Thus, we retrospectively analyzed 85 DLBCL patients aged… read more here.
Keywords: efficacy safety; lymphoma; nhl bfm; modified nhl ... See more keywords
Impact of prednisolone dosage in the CHOP regimen for follicular lymphoma: a retrospective study
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Hematology"
DOI: 10.1007/s12185-020-02908-8
Abstract: Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) is one of the standard regimens for indolent B-cell non-Hodgkin’s lymphoma (NHL). It is unclear whether the prednisolone (PSL) dosage affects the therapeutic effect or the adverse… read more here.
Keywords: indolent cell; psl day; prednisolone; dosage ... See more keywords
Primary prophylaxis with pegfilgrastim during the first cycle of R-CHOP to avoid reduction of dose intensity in elderly patients
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Hematology"
DOI: 10.1007/s12185-021-03118-6
Abstract: The long-term effects of pegfilgrastim administered in the first cycle of chemotherapy in day-to-day practice remain unclear. We retrospectively identified 114 patients aged ≥ 70 years with diffuse large B-cell lymphoma who received a rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone (R-CHOP) regimen… read more here.
Keywords: first cycle; group; cycle; pegfilgrastim group ... See more keywords